Description
HYALUBRIX is a sterile viscoelastic solution produced with salesodic hyaluronic acid obtained by bacterial fermentation from a high molecular weight fraction.
Hyaluronic acid is naturally present in many human tissues such as lacartilage and synovial fluid: it is continuously secreted in the joint cavity and represents the major component of the synovial fluid, to which it supplies its characteristic viscosity and elasticity. These properties are fundamental for the fluid to perform the functions of lubricant and shock absorber in normal joints, in order to protect the cartilage and soft tissues from mechanical damage.
In traumatic and degenerative diseases of the joints the amount of hyaluronic acid decreases and the synovial fluid loses viscosity, causing impairment of function and painful symptoms. Many studies indicate that the intra-articular administration of hyaluronic acid is able to restore the viscoelastic properties of the synovial fluid.
HYALUBRIX is a treatment for the temporary replacement of synovial fluid in patients suffering from degenerative or mechanical arthropathy, which causes an alteration of the functional performance of the synovial fluid. The intra-articular injection of HYALUBRIX at weekly intervals reduces pain symptoms and improves joint function in patients with degenerative or mechanical arthropathy for up to six months.
It is indicated for the treatment of pain and the improvement of joint function in patients with degenerative or mechanical arthropathy of the knee, hip, shoulder, ankle and trapeziometacarpal joint. The product is indicated in the treatment of persistent pain after initial failure of analgesics or in case of failure or intolerance to non-steroidal anti-inflammatory drugs.

Composition
Hyaluronic acid sodium salt 1.5%, sodium chloride, dibasic sodium phosphate 12H ₂ O, monobasic sodium phosphate 2H ₂ O, water for injectable preparations.

How to use
The injection must be strictly intra-articular. The intra-articular injection should be performed according to the standard technique, using a precise anatomic location. In the hip, shoulder, and other less easily accessible joints, ultrasound or radioscopic guidance is recommended.
All rules regarding asepsis and injection techniques must be observed.
Remove any joint effusions, if present, before administration.
Inject HYALUBRIX using a suitable sterile needle (e.g. 18 or 20 G) into the affected joint at weekly intervals for 3 weeks.
If necessary, further courses of injections may be performed, although a systematic collection of clinical data is not available. Clinical data demonstrate the efficacy of HYALUBRIX up to 6 months, however, if clinically required, the administration cycle can be repeated starting from 3 months after the first treatment cycle.

Warnings
Do not administer to patients with ascertained individual sensitivity to the components of the product. Do not administer in case of skin infections or diseases in the injection area. Do not administer to patients with active synovitis. The safety and efficacy of HYALUBRIX in pregnant women, lactating women or in individuals below 18 years of age have not been established and therefore its use is contraindicated in these patient populations. Do not use if package is damaged. Do not use the product after the expiry date stated on the package. The expiry date refers to the product stored in its con